Coherus Oncology (CHRS) Cash from Operations (2013 - 2026)

Coherus Oncology has disclosed Cash from Operations across 14 years of filings, most recently posting 57886000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 57886000.0, down 124.14% year-over-year; the trailing twelve-month figure through Mar 2026 was 170573000.0 (down 34214.6% YoY), and the FY2025 annual result was 138513000.0, down 577.66% from the prior year.
• Cash from Operations came in at 57886000.0 for Q1 2026 at Coherus Oncology, down from 19716000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 59734000.0 in Q2 2024 to a low of 99953000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 46632000.0 (2025), against an average of 37226294.12.
• Across the five-year window, Cash from Operations sank 26515.43% in 2022 and surged 321.13% in 2024, its largest moves.
• Coherus Oncology's Cash from Operations stood at 99953000.0 in 2022, then jumped by 87.06% to 12937000.0 in 2023, then soared by 321.13% to 28608000.0 in 2024, then plunged by 168.92% to 19716000.0 in 2025, then plunged by 193.6% to 57886000.0 in 2026.
• The last three Cash from Operations figures came in at 57886000.0 (Q1 2026), 19716000.0 (Q4 2025), and 46339000.0 (Q3 2025), per Business Quant data.